title: Body composition and hormonal effects following exposure to mycotoxin deoxynivalenol in the high-fat diet-induced obese mouse.
abstract: METHODS
  To characterize the effects of ingesting the common foodborne mycotoxin deoxynivalenol (DON) on body weight and composition in the high-fat (HF) diet-induced obese mice, a model of human obesity.
  
  
  RESULTS
  Female B6C3F1 mice were initially fed HF diets containing 45% kcal (HF45) or 60% kcal (HF60) as fat for 94 days to induce obesity. Half of each group was either continued on unamended HF diets or fed HF diets containing 10 mg/kg DON (DON-HF45 or DON-HF60) for another 54 days. Additional control mice were fed a low-fat (LF) diet containing 10%  kcal as fat for the entire 148-day period. DON induced rapid decreases in body weights and fat mass, which stabilized to those of the LF control within 11 days. These effects corresponded closely to a robust transient decrease in food consumption. While lean body mass did not decline in DON-fed groups, further increases were suppressed. DON exposure reduced plasma insulin, leptin, insulin-like growth factor 1, and insulin-like growth factor acid labile subunit as well as increased hypothalamic mRNA level of the orexigenic agouti-related protein.
  
  
  CONCLUSIONS
  DON-mediated effects on body weight, fat mass, food intake, and hormonal levels in obese mice were consistent with a state of chronic energy restriction.
authors.affiliation: Department of Food Science and Human Nutrition, Michigan State University, East Lansing, MI 48824, USA.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kobayashi-Hattori
authors.forename: Chidozie J
authors.initials: CJ
authors.lastname: Amuzie
authors.forename: Brenna M
authors.initials: BM
authors.lastname: Flannery
authors.forename: James J
authors.initials: JJ
authors.lastname: Pestka
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D054369:Agouti-Related Protein / Q000187:drug effects / Q000235:genetics; D000818:Animals; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D002352:Carrier Proteins / Q000097:blood / Q000187:drug effects; D004041:Dietary Fats / Q000633:toxicity; D004435:Eating / Q000187:drug effects; D002149:Energy Intake / Q000187:drug effects; D005260:Female; D006023:Glycoproteins / Q000097:blood / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000187:drug effects; D020738:Leptin / Q000097:blood; D051379:Mice; D008820:Mice, Obese; D009765:Obesity / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D012333:RNA, Messenger; D014255:Trichothecenes / Q000494:pharmacology*
chemical_list: D054369:Agouti-Related Protein; C515199:Agrp protein, mouse; D002352:Carrier Proteins; D004041:Dietary Fats; D006023:Glycoproteins; D007328:Insulin; D020738:Leptin; D012333:RNA, Messenger; D014255:Trichothecenes; C075944:insulin-like growth factor binding protein, acid labile subunit; C519530:insulin-like growth factor-1, mouse; D007334:Insulin-Like Growth Factor I; C007262:deoxynivalenol